Journal of Clinical Oncology · 2010 · 26 citations · 0 references
MedicineOncologyPharmacotherapyCancer PharmacologyChemotherapyOncology PharmacotherapyGenitourinary Cancer PharmacotherapyProstate CancerAdvanced Prostate Cancer TherapyCalcitriol TherapyCastration-resistant Prostate Cancer TherapyChemotherapy For Prostate CancerInterim AnalysisKaplan-meier Confidence IntervalsPlacebo-controlled Efficacy AssessmentProstate Cancer Hormonal Therapy
4509 Background: For Pts with progressive CRPC, a placebo-controlled phase II study suggested that combining docetaxel (D) with high-dose calcitriol (DN-101) may increase survival compared to D alone. A randomized, open-label phase III study was undertaken to compare the safety and efficacy of D plus DN-101 to D plus P. Methods: 953 men with CRPC were randomized to ASCENT arm (45 μ g DN-101, 36 mg/m2 D, and 24 mg dexamethasone (DEX) weekly for 3 out of every 4 weeks) or control arm (5 mg P twice a day, and 75 mg/m2 D and 24 mg DEX every 3 weeks). The primary endpoint was overall survival, assessed by the Kaplan-Meier method. Results: Baseline demographics were comparable between the groups. Median-follow-up for Pts alive was 11.7 months. At an interim analysis, more deaths were observed in the ASCENT arm, and the trial was halted early. Median duration of study treatment was 16.6 weeks for ASCENT subjects and 21.0 weeks for controls. The Table shows deaths at final analysis, 6 months after study termination. Median overall survival was 16.8 months (95% CI, 15.8–19.3) for ASCENT subjects and 19.9 months (95% CI, 18.6-22.7) for controls. In multivariate analysis adjusting for baseline variables, ASCENT was associated with shorter survival (HR=1.33; p=0.019). The proportions of Pts with adverse events (AEs) were similar, and consistent with the known side effects of D. Dose modification for D toxicity was more frequent in the ASCENT arm (229 ASCENT vs. 160 control subjects). Conclusions: ASCENT treatment was associated with significantly shorter survival than the control. This difference might be due to weekly D dosing in the ASCENT arm, which in the TAX 327 trial (NEJM 351:1502, 2004) appeared to be inferior to D every 3 weeks, as in the control arm of this study. Deaths in each study arm ASCENT n=477 Control n=476 Disease-specific 142 (29.8%) 108 (22.7%) Other cause 32 (6.7%) 30 (6.3%) Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novacea Novacea